Okay, now we’re using baking soda to treat cancer? Yeah, the thing sitting in the back of your fridge.

That’s the active ingredient in Dyve Biosciences‘ lead program, DYV800.

Is this snake oil?

Well, before you close this tab, hear me out, because the science behind it is surprisingly elegant.

We can start here: Tumors are acidic.

The pH inside a tumor microenvironment is lower than normal tissue, and that acidity does something very specific: it suppresses CD8+ T cells.

Your immune system’s best cancer killers show up to the fight, but the acidic environment keeps them from functioning. Checkpoint inhibitors can’t fix this. If the T cells are there but paralyzed by the pH, giving them another green light doesn’t help.

The obvious solution would be to raise the pH. Researchers have known this for years. But oral bicarbonate at therapeutic doses wrecks your GI tract. Nobody wants to drink enough baking soda to alkalinize a tumor.

Dyve’s approach is to deliver it through the skin. Transdermal. Directly to the area near the tumor. Controlled delivery, no GI toxicity, and it gets the bicarbonate where it needs to go.

The preclinical data, published in Frontiers in Immunology in collaboration with Moffitt Cancer Center, tested DYV800 in bladder cancer models.

The results showed increased intratumoral pH, restored T-cell function, reduced tumor growth, and improved survival. Specific numbers weren’t disclosed, but the peer-reviewed publication gives it more weight than a typical press release.

It’s early.

Preclinical.

Bladder cancer models.

No clinical timeline has been announced.

Dyve is based in Camarillo, California, and their company overview lists oncology, immunology, and rheumatology as target areas, which suggests they see the pH modulation approach as a platform beyond cancer.

The I-O angle is what makes this interesting. We’re spending billions trying to figure out why checkpoint inhibitors fail in certain patients and tumor types. One answer, increasingly supported by the data, is that the tumor microenvironment itself is hostile to immune function regardless of what targets you hit. DYV800 goes after the environment, not another molecular target.

Sometimes the simplest ideas are the ones nobody bothered to try properly. A first-in-class transdermal therapy that uses one of the most basic molecules in chemistry to unlock the immune system’s ability to fight cancer?

Keep an eye on this one – if only to see if they’re secretly snake oil salesmen.